
Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for violations of federal securities laws, alleging that the company made false and misleading statements regarding its product ALTO-100 and its business prospects [1][4]. Group 1: Lawsuit Details - The Schall Law Firm has initiated a class action lawsuit against Alto Neuroscience, focusing on the company's initial public offering (IPO) conducted on February 2, 2024, and the period until October 22, 2024 [1][2]. - Investors who purchased securities during the class period are encouraged to contact the firm before September 19, 2025, to discuss their rights [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Alto Neuroscience misled investors about the effectiveness of ALTO-100 in treating major depressive disorder (MDD), overstating its business and financial prospects [4]. - The company's public statements are claimed to have been false and materially misleading throughout the offering period, leading to investor damages once the truth was revealed [4].